重度慢性血栓栓塞性肺动脉高压的治疗策略

曾怡; 何田; 张静

doi:10.13201/j.issn.1001-1439.2024.09.013

重度慢性血栓栓塞性肺动脉高压的治疗策略

- 1.
  电子科技大学医学院(成都，610054)
- 2.
  四川省医学科学院·四川省人民医院呼吸与危重症医学科
- 3.
  成都中医药大学
基金项目:
四川省医学科研课题计划(No：S19011)；四川省科技计划项目(No：2022YFS0107)

详细信息

通讯作者: 张静，E-mail：zhangjing1205@uestc.edu.cn

中图分类号: R544.1

收稿日期: 2023-12-22

刊出日期: 2024-09-13

Treatment strategies for patients with severe chronic thromboembolic pulmonary hypertension

- 1.
  School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, China
- 2.
  Department of Respiratory and Critical Care Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
- 3.
  Chengdu University of Traditional Chinese Medicine

More Information

Corresponding author: ZHANG Jing, E-mail: zhangjing1205@uestc.edu.cn

Received Date: 22 December 2023

Publish Date: 13 September 2024

摘要

摘要: 慢性血栓栓塞性肺动脉高压(CTEPH)是一种致命性疾病，由于诊断延迟、诊断不充分等，大多数患者就诊时已达到重度肺动脉高压水平。对于这些重度肺动脉高压患者，单一治疗效果不佳，可选择将肺动脉内膜剥脱术(PEA)与球囊肺动脉成形术(BPA)、靶向药物相结合，以降低手术风险，或解决残余肺动脉高压。多种药物联合或BPA与药物组合为无法手术的CTEPH患者提供了新的治疗选择。本文旨在为重度CTEPH患者的治疗，尤其是联合治疗方案的选择提供参考。
- 肺动脉高压, 血栓栓塞性, 慢性 /
- 肺动脉内膜剥脱术 /
- 球囊肺动脉成形术
Abstract: Chronic thromboembolic pulmonary hypertension(CTEPH) is a fatal disease. Due to delayed diagnosis or inadequate diagnosis, most patients have reached the level of severe pulmonary hypertension at the time of diagnosis. For patients with severe pulmonary hypertension, a single treatment is not effective. Pulmonary endarterectomy(PEA) can be combined with balloon pulmonary angioplasty(BPA) or targeted drugs to reduce the risk of surgery or solve residual pulmonary hypertension. Multiple drug combinations or BPA in combination with drugs provide new treatment options for patients with inoperable CTEPH. This article aims to provide a reference for treating patients with severe CTEPH, especially the choice of combined treatment options.
- chronic thromboembolic pulmonary hypertension /
- pulmonary endarterectomy /
- balloon pulmonary angioplasty

HTML全文

参考文献(48)

[1]	Yang J, Madani MM, Mahmud E, et al. Evaluation and Management of Chronic Thromboembolic Pulmonary Hypertension[J]. Chest, 2023, 164(2): 490-502. doi: 10.1016/j.chest.2023.03.029
[2]	Jenkins D. Pulmonary endarterectomy: the potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension[J]. Eur Respir Rev, 2015, 24(136): 263-271. doi: 10.1183/16000617.00000815
[3]	Delcroix M, Lang I, Pepke-Zaba J, et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry[J]. Circulation, 2016, 133(9): 859-871. doi: 10.1161/CIRCULATIONAHA.115.016522
[4]	Wiedenroth CB, Rolf A, Steinhaus K, et al. Riociguat and balloon pulmonary angioplasty improve prognosis in patients with inoperable chronic thromboembolic pulmonary Hypertension[J]. J Heart Lung Transplant, 2023, 42(1): 134-139. doi: 10.1016/j.healun.2022.08.011
[5]	Kerr KM, Elliott CG, Chin K, et al. Results from the United States chronic thromboembolic pulmonary hypertension registry: enrollment characteristics and 1-year follow-up[J]. Chest, 2021, 160(5): 1822-1831. doi: 10.1016/j.chest.2021.05.052
[6]	Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Respir J, 2023, 61(1): 2200879. doi: 10.1183/13993003.00879-2022
[7]	Sznajder M, Dzikowska-Diduch O, Kurnicka K, et al. Increased systemic arterial stiffness in patients with chronic thromboembolic pulmonary hypertension[J]. Cardiol J, 2020, 27(6): 742-748. doi: 10.5603/CJ.a2018.0109
[8]	Papamatheakis DG, Poch DS, Fernandes TM, et al. Chronic thromboembolic pulmonary hypertension: JACC focus seminar[J]. J Am Coll Cardiol, 2020, 76(18): 2155-2169. doi: 10.1016/j.jacc.2020.08.074
[9]	de Perrot M, Gopalan D, Jenkins D, et al. Evaluation and management of patients with chronic thromboembolic pulmonary hypertension-consensus statement from the ISHLT[J]. J Heart Lung Transplant, 2021, 40(11): 1301-1326. doi: 10.1016/j.healun.2021.07.020
[10]	Delcroix M, Torbicki A, Gopalan D, et al. ERS statement on chronic thromboembolic pulmonary hypertension[J]. Eur Respir J, 2021, 57(6): 2002828. doi: 10.1183/13993003.02828-2020
[11]	Kianzad A, Baccelli A, Braams NJ, et al. Long-term effects of pulmonary endarterectomy on pulmonary hemodynamics, cardiac function, and exercise capacity in chronic thromboembolic pulmonary hypertension[J]. J Heart Lung Transplant, 2024, 43(4): 580-593. doi: 10.1016/j.healun.2023.11.011
[12]	de Perrot M, McRae K, Donahoe L, et al. Pulmonary endarterectomy in severe chronic thromboembolic pulmonary hypertension: the Toronto experience[J]. Ann Cardiothorac Surg, 2022, 11(2): 133-142. doi: 10.21037/acs-2021-pte-14
[13]	Fukuda K, Date H, DoiS, et al. Guidelines for the treatment of pulmonary hypertension(JCS 2017/JPCPHS 2017)[J]. Circ J, 2019, 83(4): 842-945. doi: 10.1253/circj.CJ-66-0158
[14]	Guth S, D'Armini AM, Delcroix M, et al. Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry[J]. ERJ Open Res, 2021, 7(3): 00850-02020.
[15]	Wunder F, Stasch JP, Knorr A, et al. Identification and characterization of the new generation soluble guanylate cyclase Stimulator BAY-747 designed for the treatment of resistant hypertension[J]. Br J Pharmacol, 2023, 180(19): 2500-2513. doi: 10.1111/bph.16142
[16]	Sadushi-Kolici R, Jansa P, Kopec G, et al. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension(CTREPH): a double-blind, phase 3, randomised controlled trial[J]. Lancet Respir Med, 2019, 7(3): 239-248. doi: 10.1016/S2213-2600(18)30367-9
[17]	Ghofrani HA, Simonneau G, D'Armini AM, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension(MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study[J]. Lancet Respir Med, 2024, 12(4): e21-e30. doi: 10.1016/S2213-2600(24)00027-4
[18]	López-Gude MJ, Blanco I, Benito-Arnáiz V, et al. Pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension: the Spanish experience[J]. Ann Cardiothorac Surg, 2022, 11(2): 151-160. doi: 10.21037/acs-2021-pte-18
[19]	Jenkins D, Madani M, Fadel E, et al. Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension[J]. Eur Respir Rev, 2017, 26(143): 160111. doi: 10.1183/16000617.0111-2016
[20]	Shimahara Y, Suzuki S, Fujiyoshi T, et al. Balloon pulmonary angioplasty followed by pulmonary endarterectomy: Combination treatment for high-surgical-risk patients with chronic thromboembolic pulmonary hypertension[J]. Interdiscip Cardiovasc Thorac Surg, 2023, 36(3): ivad031.
[21]	Mercier O, Dubost C, Delaporte A, et al. Pulmonary thromboendarterectomy: the Marie lannelongue hospital experience[J]. Ann Cardiothorac Surg, 2022, 11(2): 143-150. doi: 10.21037/acs-2021-pte-20
[22]	Kawashima T, Yoshitake A, Kawakami T, et al. Two-stage treatment using balloon pulmonary angioplasty and pulmonary endarterectomy in a patient with chronic thromboembolic pulmonary hypertension[J]. Ann Vasc Surg, 2018, 49: 315. e5-315315. e7. doi: 10.1016/j.avsg.2017.11.057
[23]	Danilov NM, Karabasheva MB, Sagaydak OV, et al. Hybrid approach for treating patient with chronic thromboembolic pulmonary hypertension and extrinsic compression of left main coronary artery[J]. Russian Open Med J, 2019, 8(4), 407.
[24]	Astashchanka A, Kerr KM, Yang JZ, et al. Repeat pulmonary thromboendarterectomy outcomes: A 15-year single-center retrospective review[J]. J Thorac Cardiovasc Surg, 2023, 166(6): 1512-1519. e2. doi: 10.1016/j.jtcvs.2023.02.028
[25]	Maneiro Melon NM, Velazquez Martin M, Huertas Nieto S, et al. Effectiveness and safety of balloon pulmonary angioplasty for the treatment of patients with persistent pulmonary hypertension after pulmonary endarterectomy[J]. J Clin Med, 2023, 12(3): 905. doi: 10.3390/jcm12030905
[26]	Atas H, Mutlu B, Akaslan D, et al. Balloon pulmonary angioplasty in patients with inoperable or recurrent/residual chronic thromboembolic pulmonary hypertension: a single-centre initial experience[J]. Heart Lung Circ, 2022, 31(4): 520-529. doi: 10.1016/j.hlc.2021.10.009
[27]	Nishiyama M, Inoue Y, Sasaki H, et al. Long-term outcomes of combined pulmonary endarterectomy and additional balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension[J]. Gen Thorac Cardiovasc Surg, 2023, 71(5): 291-298. doi: 10.1007/s11748-022-01872-w
[28]	Astashchanka A, Fernandes T, Papamatheakis DG, et al. Risk factors and outcomes for patients requiring repeat thromboendarterectomy[J]. Am J Respir Crit Care Med, 2020, 201: A6065.
[29]	Wiedenroth CB, Liebetrau C, Breithecker A, et al. Combined pulmonary endarterectomy and balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension[J]. J Heart Lung Transplant, 2016, 35(5): 591-596. doi: 10.1016/j.healun.2015.10.030
[30]	Madani M, Higgins J. Minimally invasive pulmonary thromboendarterectomy: a novel technique[EB/OL]. In: ISMICS, New York, NY, USA, 29th May to 1st June 2019.
[31]	Kunihara T, Wilkens H, Halank M, et al. Haemodynamic benefit of bridging use of bosentan prior to pulmonary endarterectomy[J]. Eur J Cardiothorac Surg, 2021, 60(4): 840-847. doi: 10.1093/ejcts/ezab137
[32]	Balasubramanian VP, Beutner M, Gill K, et al. Real-world experience with riociguat as potential bridging therapy in patients with chronic thromboembolic pulmonary hypertension: a case series[J]. Pulm Circ, 2020, 10(2): 2045894019898377.
[33]	Castro MA, Piloto B, Dos Santos Fernandes CJC, et al. Use of medical therapies before pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension patients with severe hemodynamic impairment[J]. PLoS One, 2020, 15(5): e0233063. doi: 10.1371/journal.pone.0233063
[34]	de Perrot M, Donahoe L, McRae K, et al. Outcome after pulmonary endarterectomy for segmental chronic thromboembolic pulmonary hypertension[J]. J Thorac Cardiovasc Surg, 2022, 164(3): 696-707. e4. doi: 10.1016/j.jtcvs.2021.10.078
[35]	Jensen KW, Kerr KM, Fedullo PF, et al. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy[J]. Circulation, 2009, 120(13): 1248-1254. doi: 10.1161/CIRCULATIONAHA.109.865881
[36]	Jansa P, Ghofrani HA, Hoeper MM, et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension(CTEPH)in the Phase Ⅲ CHEST-1 study[J]. Eur Heart J, 2013, 34(suppl_1): 1066.
[37]	Wiedenroth CB, Ghofrani HA, Adameit MSD, et al. Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension[J]. Pulm Circ, 2018, 8(3): 2045894018783996.
[38]	Jaïs X, Brenot P, Bouvaist H, et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension(RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study[J]. Lancet Respir Med, 2022, 10(10): 961-971. doi: 10.1016/S2213-2600(22)00214-4
[39]	Gerges C, Friewald R, Gerges M, et al. Efficacy and safety of percutaneous pulmonary artery subtotal occlusion and chronic total occlusion intervention in chronic thromboembolic pulmonary hypertension[J]. Circ Cardiovasc Interv, 2021, 14(8): e010243. doi: 10.1161/CIRCINTERVENTIONS.120.010243
[40]	廖梦阳, 高兴丽, 梁薇, 等. 肺动脉球囊扩张成形术在慢性血栓栓塞性肺高压治疗中的临床意义和技术要点[J]. 临床心血管病杂志, 2023, 39(2): 88-92. doi: 10.13201/j.issn.1001-1439.2023.02.003
[41]	Kimura M, Kohno T, Shinya Y, et al. De-escalation of oxygen therapy and medication in patients with chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty[J]. Can J Cardiol, 2023, 39(5): 637-645. doi: 10.1016/j.cjca.2023.01.014
[42]	Hasler ED, Müller-Mottet S, Furian M, et al. Pressure-flow during exercise catheterization predicts survival in pulmonary hypertension[J]. Chest, 2016, 150(1): 57-67. doi: 10.1016/j.chest.2016.02.634
[43]	Aoki T, Sugimura K, Terui Y, et al. Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty-A randomized controlled study[J]. Int J Cardiol Heart Vasc, 2020, 29: 100579.
[44]	Gall H, Preston IR, Hinzmann B, et al. An international physician survey of chronic thromboembolic pulmonary hypertension management[J]. Pulm Circ, 2016, 6(4): 472-482. doi: 10.1086/688084
[45]	Swisher JW, Elliott D. Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension[J]. Respir Med Case Rep, 2017, 20: 45-47.
[46]	Tanabe N, Fukuda K, Matsubara H, et al. Selexipag for chronic thromboembolic pulmonary hypertension in Japanese patients-A double-blind, randomized, placebo-controlled, multicenter phase Ⅱ study[J]. Circ J, 2020, 84(10): 1866-1874. doi: 10.1253/circj.CJ-20-0438
[47]	Gabrielly M, Bourlier D, Taniguchi Y, et al. Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension(CTEPH)[J]. Eur Respir J, 2018, 52(suppl 62): PA3053.
[48]	van Thor MCJ, Snijder RJ, Kelder JC, et al. Does combination therapy work in chronic thromboembolic pulmonary hypertension?[J]. Int J Cardiol Heart Vasc, 2020, 29: 100544.